Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - COMPASS Pathways

Drug Profile

Psilocybin - COMPASS Pathways

Alternative Names: COMP-360; Psilocybine

Latest Information Update: 16 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator COMPASS Pathways
  • Developer COMPASS Pathways; Yale University
  • Class Antidepressants; Indoles; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action Serotonin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Depressive disorders
  • Phase II Headache

Most Recent Events

  • 14 Jan 2020 COMPASS Pathways has patent protection for COMP 360 in USA
  • 17 Dec 2019 Phase-I clinical trials in Depressive disorders (In volunteers) in United Kingdom (PO) (EudraCT2018-000978-30) before December 2019
  • 12 Dec 2019 Adverse events data in Healthy volunteers released by COMPASS Pathways
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top